Placing of new shares under general mandate
Filed with HKEX · Stock code 858 · · 10 pages · English
Summary by 6ix AI
The proceeds from this placing are intended to support the expansion of the company's trading and manufacturing operations in electronic modules and related products. The completion of the placing is subject to certain conditions, and shareholders are advised to exercise caution as the transaction may or may not proceed.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Extrawell Pharmaceutical Holdings Limited on 6ix
Earlier from Extrawell Pharmaceutical
- Grant of share options to directors and connected transaction at subsidiary level in relation to the grant of share options to the service Provider
- Termination of the memorandum of understanding in relation to the possible sale of the convertible bonds
- Proposed share consolidation; proposed capital Reduction; proposed share sub-division and proposed change in board lot size
- List of directors and their roles and functions
- Appointment of executive director
Later from Extrawell Pharmaceutical
- Further delay in despatch of the circular and further extension of the long stop date in relation to the major transaction involving the proposed fourth amendments to the terms and Conditions of the bonds
- Proposed share consolidation; proposed capital reduction; proposed share sub-division; proposed change in board lot size and notice of special general meeting
- Form of proxy for special general meeting to be held on Monday, 30 November 2026 at 10: 00 a.m.
- Notice of special general meeting
- NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - Notice of Publication of Circular containing Notice of Special General Meeting dated 6 November 2026 and Proxy Form
Follow Extrawell Pharmaceutical into a list and get an email when it puts out news.
Follow Extrawell Pharmaceutical